论文部分内容阅读
目的:探讨枸橼酸莫沙比利分散片联合雷贝拉唑钠肠溶胶囊治疗功能性消化不良的临床疗效和安全性。方法:将重庆市沙坪坝区陈家桥医院2012年12月至2013年12月收治的58例确诊为功能性消化不良患者随机分为对照组以及观察组,各29例,观察组用枸橼酸莫沙比利分散片联合雷贝拉唑钠肠溶胶囊治疗,对照组用雷贝拉唑钠肠溶胶囊治疗4周,比较两组的疗效及副反应。结果:观察组在用药四周后的餐后饱胀、上腹疼痛单相评分以及症状总分均有显著下降(P<0.01),且观察组总有效率44.8%显著高于对照组的6.8%(P<0.01)。两组的不良反应均较轻微。结论:枸橼酸莫沙比利分散片联合雷贝拉唑钠肠溶胶囊治疗功能性消化不良疗效较肯定,不良反应少。
Objective: To investigate the clinical efficacy and safety of mosapride citrate dispersible tablets combined with rabeprazole sodium enteric-coated capsules in the treatment of functional dyspepsia. Methods: Fifty-eight patients with functional dyspepsia diagnosed in Chenjiaqiao Hospital of Shapingba District in Chongqing from December 2012 to December 2013 were randomly divided into control group and observation group, with 29 cases in each group. The observation group was treated with mosapride citrate Billy dispersible tablets combined with rabeprazole sodium enteric-coated capsules treatment, the control group with rabeprazole sodium enteric-coated capsules for 4 weeks, the efficacy and side effects were compared between the two groups. Results: The postprandial fullness of appetite, the single-phase pain score and the total score of symptoms in the observation group decreased significantly (P <0.01), and the total effective rate in the observation group was 44.8% significantly higher than that in the control group (P <0.01). Adverse reactions were mild in both groups. Conclusion: Mosapride citrate dispersible tablets combined with rabeprazole sodium enteric-coated capsules are more effective in treating functional dyspepsia with less adverse reactions.